[ad_1]
Byzencell was evaluated by two specialized evaluation agencies appointed by the Korea Stock Exchange in various fields, including the integrity and growth potential of the company, the growth potential of the company and the level of workforce, and acquired the ratings A and BBB and approved the technology. evaluation, said Boryeong Pharmaceutical.
Boryung Pharmaceutical participated in Weizen Cell as a financial investor in 2016. Customized T-cell therapy platform technology using antigen-specific cytotoxic T cells (CTL) ‘ViTier’, universal immunosuppressive cell therapy platform technology ‘ViMedier’, platform of gamma delta T cell-based universal T-cell therapy is currently developing six new drugs based on three platform technologies such as ‘ViRanger’.
The main new drug project is a phase 2 clinical trial for ‘VT-EBV-N’, a rare and untreatable disease ‘NK / T cell lymphoma’ without a standard treatment method, and was designated as an orphan drug in the development stage. by the Ministry of Food and Pharmaceutical Safety in October 2019. Once the award is finalized, it is preparing for commercialization by obtaining a conditional permit for the item.
Additionally, a 1 / 2a clinical trial was approved last year for ‘VMGD’, an immune cell therapy using ‘GvHD’ (GvHD), which is seen primarily in bone marrow transplant patients. (1) -A ‘has also been approved for a phase 1 clinical trial last year, and plans to begin a clinical trial this year.
Tae-gyu Kim, CEO of Weigen Cell, said: “Based on the approval of this technology assessment, we plan to promote the listing in the third quarter.” “We plan to increase the market value of companies by concentrating our capabilities on discovering new drugs that use technology.”
Copyright © News Free Zone Unauthorized reproduction and redistribution prohibited
